Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Beijing Xunsheng Biomedical Research Co., Ltd.

Clinicaltrial registered17 Nov 2026

Beijing Xunsheng Biomedical Research Co., Ltd.

17 Nov 2026: Trial registered · AVL-102 for the Treatment of HPV 16/18/52/58-Related High-Grade Lesions. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
17 Nov 2026
Title
AVL-102 for the Treatment of HPV 16/18/52/58-Related High-Grade Lesions
Conditions
CIN 2/3, HPV Infections
Phase
Phase 1
Study Type
Interventional
Status
Recruiting
Countries
China
Country
China
Reference
NCT07942779
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Beijing Xunsheng Biomedical Research Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Beijing Xunsheng Biomedical Research Co., Ltd. in our registers.

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.